Abstracts tagged "Myositis"

Abstract Number: 0280 • ACR Convergence 2025
Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.
Suchada Kaewin¹, Cecilia Leijding², Kristofer Andreasson², Helene Alexanderson³, Stefano Gastaldello¹, Ingrid Lundberg² and Daniel C. Andersson², ¹Karolinska Institutet, inst fysiologi och farmakologi, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Dermatomyositis (DM) is a major subtype of idiopathic inflammatory myopathies (IIMs) and characterized by muscle weakness, systemic inflammation and cutaneous lesions. Expression of type…
Abstract Number: 0304 • ACR Convergence 2025
Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region
Takahisa Gono¹, Vidya Limaye², Latika Gupta³, Vikas Agarwal⁴, Ho So⁵, JASMIN RAJA⁶, Warren Weng Seng Fong⁷, Suparaporn Wangkaew⁸, Andrea Low⁹, Akihiro Murakami¹⁰, Kimiko Hasegawa¹⁰, Takuya Isayama¹¹ and Masataka Kuwana¹, ¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶University Malaya, Subang Jaya, Malaysia, ⁷Singapore General Hospital, Singapore, ⁸Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, ⁹Singapore General Hospital, Singapore, Singapore, ¹⁰Medical & Biological Laboratories co., ltd., Tokyo, ¹¹Medical & Biological Laboratories co., ltd., Tokyo, Japan
Background/Purpose: RNA/protein immunoprecipitation (IP) assays remain the “gold standard” for myositis-specific autoantibody (MSA) detection. However, the requirements for large-scale cell culture and radioisotopes limit its…
Abstract Number: 1195 • ACR Convergence 2025
Discordance between Immunoblot and ELISA in the detection of Jo-1 and Ro/Ro-52 Autoantibodies
Antonia Valenzuela¹, Sebastián Andrés Cerda Acevedo² and Francisco Vera Gutiérrez², ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Pontificia Universidad Católica de Chile, Santiago de Chile, Chile
Background/Purpose: Autoantibodies play a key role in the diagnosis, classification, and prognosis of idiopathic inflammatory myopathies (IIM). Among the most relevant are myositis-specific antibodies (MSAs),…
Abstract Number: 1216 • ACR Convergence 2025
Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies
Sung-Ki Lee¹, Kristin Wipfler², Ethan Ritz³, Burcu Aydemir⁴, Kaleb Michaud⁵ and Didem Saygin⁶, ¹Rush Medical College, Chicago, IL, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Rush University Medical Center, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune disorders characterized by chronic skeletal muscle inflammation leading to muscle weakness and limitations in physical…
Abstract Number: 2063 • ACR Convergence 2025
Linking PROMIS scores to disease severity and treatment in dermatomyositis: a patient-centered evaluation
Julie Paik¹, Andrea Young², Zuzana Bologna³, Will Kelly³, Chris Mecoli⁴, Jemima Albayda² and Lisa Christopher-Stine², ¹Johns Hopkins Rheumatology, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a chronic inflammatory myopathy characterized by muscle weakness and skin rashes, yet its full impact on patient-reported outcomes remains under-explored. We…
Abstract Number: 2673 • ACR Convergence 2025
Quantitative 18F-FDG PET/CT analysis reveals new patterns of muscle involvement and prognostic indicators in idiopathic inflammatory myopathies: beyond proximal muscle weakness
Fatma Basibuyuk¹, Melih Yigithan Bahadir², Gokce Kenar Artin², Amac Kiray², Recep Bekis² and İsmail Sari², ¹Dokuz Eylul University, Izmir, Turkey, ²Dokuz Eylül University, İzmir, Izmir, Turkey
Background/Purpose: To characterize muscle involvement in idiopathic inflammatory myopathies (IIMs) using detailed anatomical segmentation and volumetric 18F-FDG PET/CT analysis, and to evaluate the prognostic value…
Abstract Number: 0283 • ACR Convergence 2025
The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records
Ana Valle¹, Amy Vo², Rochelle Castillo¹, Yumeko Kawano³, Leah Santacroce³, Daniel Solomon⁴, Katherine Liao³ and Candace Feldman³, ¹Brigham and Women's Hospital, Brookline, MA, ²Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Idiopathic inflammatory myopathies (IIM; including dermatomyositis, polymyositis, and inclusion body myositis) are heterogenous systemic inflammatory conditions that cause significant disability and morbidity. The study…
Abstract Number: 0305 • ACR Convergence 2025
From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
Vaidehi Kothari¹, Eaman Alhassan², Kevin Renz Ambrocio¹, Bonny Rockette-Wagner³, Chester V. Oddis¹, Kendrea (Focht) Garand¹ and Rohit Aggarwal⁴, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh, PITTSBURGH, ⁴University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…
Abstract Number: 1196 • ACR Convergence 2025
Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies
Anuya Natu¹, Haley Zimmerman², Kristin Wipfler³, Kaleb Michaud⁴, Yvonne Lee⁵ and Didem Saygin², ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Northwestern University, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) can be associated with significant pain and functional impairment. While the use of opioids has been documented in other inflammatory…
Abstract Number: 1217 • ACR Convergence 2025
Validation and clincial use of anti-MDA5 test – LIA versus ELISA
TING-YUAN LAN¹, pei-Hsinq lai², Tai-Ju Lee³, Ting-Wei Chang⁴, Kuan-Yen Lin⁵, Shao-Yu Pai⁶ and Ko-Jen Li⁷, ¹National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ²Taipei City Hospital, Taichung, Taiwan, ³National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ⁵National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City, Taiwan (Republic of China), ⁶National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), ⁷National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Although immunoprecipitation (IP) remains the gold standard for detecting myositis autoantibodies, it is technically demanding and not widely available. Line immunoassay (LIA) has become…
Abstract Number: 2064 • ACR Convergence 2025
Kinematics Underlying IBM-induced Dysphagia
Kevin Renz Ambrocio¹, Vaidehi Kothari¹, Rohit Aggarwal², Anna Miles³, James L. Coyle¹, Eaman Alhassan⁴, Sandra Stinnett¹, David Lacomis¹, Lea Sayce¹ and Kendrea (Focht) Garand¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ³The University of Auckland, Auckland, New Zealand, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Dysphagia remains a key contributor to mortality in IBM due to its connection with aspiration pneumonia and malnutrition (Shelly et al., 2021). Compared to…
Abstract Number: PP01 • ACR Convergence 2025
When You Become the Story: A Journalist’s Approach to Managing Complex Care
Lindsay Guentzel
Background/Purpose: As a journalist, I’ve spent my career digging for answers. But when I became the story, I had to learn how to ask the…
Abstract Number: 0284 • ACR Convergence 2025
Glucocorticoid Tapering and Relapse Risk in Anti-ARS Antibody-Positive Myositis: A Retrospective Study in a Single-Center Cohort Treated with Immunosuppressants
Ayaka Inoue¹, Takashi Yamane², Noriaki Yasuda³ and Takahisa Ohnishi¹, ¹Kakogawa Central City Hospital, Kakogawa, Japan., kakogawa-cho, kakogawa city, Hyogo, Japan, ²Kakogawa Central City Hospital, Kobe, Hyogo, Japan, ³Kakogawa Central City Hospital, Kakogawa, Japan
Background/Purpose: Anti–synthetase syndrome is generally responsive to glucocorticoid (GC) therapy, though relapse frequently complicates tapering. Prolonged GC use is associated with adverse events and decreased…
Abstract Number: 0344 • ACR Convergence 2025
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Gregory Challener¹, Zandra E. Walton¹, Christine M. Parsons¹, Aakash V. Patel², Alex Tinianow³, Molly E. Griffin¹, Raisa Lomanto Silva³, Avira Som¹, Laura J. Yockey⁴, WuQiang Fan⁵, Sheila L. Arvikar¹ and Marcy Bolster⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴MGH, Charlestown, MA, ⁵Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, ⁶Massachusetts General Hospital, Concord, MA
Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…
Abstract Number: 1197 • ACR Convergence 2025
Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation
Bandana Jassal¹, Aishwarya Dhall¹, Mohammed Faruq², Danveer Bhadu¹, Uma Kumar¹ and Mehar Chand Sharma¹, ¹All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India, ²Institute of Genomics and Integrative Biology, New Delhi, Delhi, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune muscle disorders with complex genetic underpinnings. Most genetic studies have focused on limited populations. This study explores…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].